Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Richard Kuntz joins Tengion's board

This article was originally published in Clinica

Executive Summary

Regenerative medicine specialist Tengion has appointed Richard Kuntz to its board of directors. Dr Kuntz is currently Medtronic's senior vice-president and chief scientific, clinical and regulatory officer. Before joining Medtronic in 2005, he was founder and chief scientific officer of the Harvard Clinical Research Institute, a contract research organisation based at the university. Dr Kuntz has directed over 100 multicentre clinical trials and has authored more than 200 scientific papers, and has experience in developing both pharmaceuticals and medical devices. East Norriton, Pennsylvania-based Tengion's technology is designed to regenerate organs and tissues from patients' own cells. Its most advanced product is the Neo-Bladder Augment, which has completed two Phase II trials in patients with neurogenic bladder (when the nerves controlling bladder function do not work properly).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel